Belgium

After announcing updates in its ongoing legal battle and a leadership shakeup earlier this fiscal year, Hyloris closed 2024 with a slight rise in revenue and a shrinking of its reported net loss.

Roche is in the crosshairs of the Belgian Competition Authority for allegedly delaying the entry of rituximab and trastuzumab biosimilars between 2017 and 2020, after the BCA sent the firm a statement of objections over “exclusionary practices.”

Roche is in the crosshairs of the Belgian Competition Authority for allegedly delaying the entry of rituximab and trastuzumab biosimilars between 2017 and 2020, after the BCA sent the firm a statement of objections over “exclusionary practices.”

Following steady updates on its development of a new formulation of valacyclovir, Hyloris revealed the US FDA’s acceptance of its NDA filing while also announcing three new deals this month.

The commercialization of the generic version of Hospira’s THAM solution will be carried out by A.forall’s US subsidiary Milla Pharmaceuticals.

The Belgian health technology assessment agency will also lead on joint scientific consultations, which will be instrumental in helping companies submit appropriate dossiers for joint clinical assessments.

New updates to 2006 regulations expand the existing framework governing drug shortages in Belgium.

Delegates from European institutions and industry representatives unpacked the many challenges of improved access to critical medicines on the continent in a session at this year’s European Health Forum.

Hyloris’ dispute with AltaThera over the cardiovascular drug Sotalol IV has reached another milestone with a final verdict from an arbitration panel, which cleared Hyloris of financial liabilities while also denying its own claims.

Sanofi CHC names new Italy country manager; Uriach appoints head of France & Belgium; EFSA announces leadership of Scientific Committee.